We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information
Thank you for submitting your question. You will get a reply within two business days to the email you provided. Thank you.
Completed
Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus - AI444-043
Updated:
22 December, 2015
|
ClinicalTrials.gov
This clinical trial is now complete.
For clinical trial results please visit ClinicalTrials.gov.
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information
Have questions? Live support is available 24/7 - Call 855-907-3286 or email clinical.trials@bms.com